Beyond oncology - Application of HPMA copolymers in non-cancerous diseases

Xin Ming Liu; Scott C. Miller; Dong Wang

doi:10.1016/j.addr.2009.10.006

Beyond oncology - Application of HPMA copolymers in non-cancerous diseases

Xin Ming Liu, Scott C. Miller, Dong Wang

Research output: Contribution to journal › Review article

28 Scopus citations

Abstract

Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.

Original language	English (US)
Pages (from-to)	258-271
Number of pages	14
Journal	Advanced Drug Delivery Reviews
Volume	62
Issue number	2
DOIs	https://doi.org/10.1016/j.addr.2009.10.006
Publication status	Published - Feb 17 2010

Fingerprint

Keywords

Arthritis
Bone-targeting
Central nervous system (CNS)
HPMA copolymers
Infectious diseases
Musculoskeletal diseases

ASJC Scopus subject areas

Pharmaceutical Science

Cite this

Liu, X. M., Miller, S. C., & Wang, D. (2010). Beyond oncology - Application of HPMA copolymers in non-cancerous diseases. Advanced Drug Delivery Reviews, 62(2), 258-271. https://doi.org/10.1016/j.addr.2009.10.006

@article{caa15f64c0ad4efcb9b18ea2af453aee,

title = "Beyond oncology - Application of HPMA copolymers in non-cancerous diseases",

abstract = "Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.",

keywords = "Arthritis, Bone-targeting, Central nervous system (CNS), HPMA copolymers, Infectious diseases, Musculoskeletal diseases",

author = "Liu, {Xin Ming} and Miller, {Scott C.} and Dong Wang",

year = "2010",

month = "2",

day = "17",

doi = "10.1016/j.addr.2009.10.006",

language = "English (US)",

volume = "62",

pages = "258--271",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Beyond oncology - Application of HPMA copolymers in non-cancerous diseases

AU - Liu, Xin Ming

AU - Miller, Scott C.

AU - Wang, Dong

PY - 2010/2/17

Y1 - 2010/2/17

N2 - Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.

AB - Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.

KW - Arthritis

KW - Bone-targeting

KW - Central nervous system (CNS)

KW - HPMA copolymers

KW - Infectious diseases

KW - Musculoskeletal diseases

UR - http://www.scopus.com/inward/record.url?scp=75749129808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749129808&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2009.10.006

DO - 10.1016/j.addr.2009.10.006

M3 - Review article

C2 - 19909776

AN - SCOPUS:75749129808

VL - 62

SP - 258

EP - 271

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 2

ER -

Access to Document

10.1016/j.addr.2009.10.006